| Ytd | -14.09% | |
| 1y | -15.13% |
| Open | 42.33 | Prev Close | 42.66 | Low | 41.27 | High | 42.36 | Mkt Cap | 99.65B |
| Vol | 4.50M | Avg Vol | 3.13M | EPS | 2.26 | P/E | 18.42 | Forward P/E | 7.87 |
| Beta | 0.28 | Short Ratio | 2.60 | Inst. Own | 8.88% | Dividend | 2.42 | Div Yield | 5.67 |
| Ex Div Date | 05-04 | Earning | 07-30 | 50-d Avg | 43.89 | 200-d Avg | 46.94 | 1yr Est | 55.90 |
SNY News
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease,
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typica
Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a plan
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3
EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany an
The European Commission opened on Friday an investigation into whether French drug giant Sanofi br
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 bill
Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma p
Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chr
Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for s
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its
FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 di
Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to d
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read
Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered
Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed
"Concierge For The Field" is an AI agent that preps sales reps for meetings with physicians